Combating prescription drug abuse: an interview with Mark Trudeau and Carmen Catizone

NewsGuard 100/100 Score
insights from industryMark TrudeauPresident and Chief Executive Officer of
Mallinckrodt Pharmaceuticals. 
Carmen Catizone Executive Director, National Association of
Boards of Pharmacy (NABP)

Why is prescription drug abuse a growing problem?

Mark Trudeau: Prescription drug abuse is an extremely complex problem with no single solution.

For example, the very same medications that are so critical for alleviating pain in legitimate patients could easily be diverted and misused by other people. In addition, something as basic as failing to discard old, unused medications could lead to abuse.

Now, more than ever, we need to create awareness and dialogue about appropriate access to pain management and responsible use of pain medications, including proper disposal, to ensure that legitimate patients continue to have access to the medications they need and to help reduce prescription drug abuse.

What are the main warning signs pharmacists should look for to identify a potential abuser?

Carmen Catizone: There are no specific criteria for identifying a potential abuser.  Every situation is unique and will need to be evaluated at the time using the information available and the professional judgment of the pharmacist.

However, with that in mind, there are some behaviors or situations that generally should cause concern and identified as possible red flags indicative of potential abuse and diversion. These include: 

  1. Behavior of the person presenting the prescription - are they agitated, nervous, or behaving in a suspicious manner?
  2. Situation surrounding the presentation of the prescription – did they arrive in a group, are locations of the prescriber, pharmacy, and patient in relation to one another geographically inconsistent, that is, significant distances apart for no logical reason, or is there activity occurring such as the presentation of large amounts of cash or the exchange of cash among customers?
  3. Prescription – there are several areas of consideration concerning the actual prescription, the medication, strength, quantity, and combination of medicines.

Why should pharmacists be cautious of customers who present in groups?

Carmen Catizone: The caution that exists with patients arriving in groups is best explained by looking at two questions pharmacists should ask themselves - what normally occurs when a patient presents a prescription and what has experiences and information from law enforcement agencies taught us about the diversion and abuse of controlled substances?

The first question can be answered by anyone who has ever had their prescription filled at a pharmacy. The usual scenario is for a patient to present a prescription issued by a prescriber to the pharmacist. Doing so does not involve traveling with a group and presenting at the pharmacy at the same time.

The plausibility of a group of people seeing the same prescriber on the same day and then traveling as a group to the same pharmacy seems incredibly low and frankly, just isn’t the norm and doesn’t make sense.

This is borne out from our experience in detecting and combatting prescription drug abuse and diversion and information from law enforcement agencies. In instances where abuse and diversion occurs and occurred, people traveling in groups has been a consistent red flag.

How can a pharmacist decide whether a prescription passes the truth test?

Carmen Catizone: A pharmacist is educated and trained to evaluate situations every day and with every patient in order to make a decision on whether a prescription is for a legitimate medical need and thus pass the truth test.

The decision draws from the extensive training and education a pharmacist receives prior to being licensed to practice and the red flags that should be detected when the prescription is presented. 

What questions should a pharmacist ask to question the validity of a prescription?

Carmen Catizone: There are a number of questions a pharmacist should ask when evaluating the validity of a prescription. The questions should focus on the reason for the issuance of the prescription, the patient’s understanding of what the prescription was issued for (symptoms or medical condition), the relationship between the patient and the prescriber, and information about the patient concerning allergies, other medications being taken, and special considerations.

Such an interaction will alert the pharmacist to important red flags that will help with making the decision on whether the prescription is for a legitimate medical purpose.

How are Mallinckrodt reinforcing responsible pain management?

Mark Trudeau:  Mallinckrodt is committed to ensuring the appropriate use of prescription pain medicines. We are investing in the use of abuse-deterrent technology, actively working to integrate federal and state prescription drug monitoring programs, enhancing suspicious order monitoring, drug take-back, addiction, and rehabilitation programs, collaborating with other organizations to promote proper disposal methods and developing and sharing best practices and stakeholder education for patients, providers and the public at large.

What are Mallincrkodt’s plans for the future?

Mark Trudeau: We are focusing on what we do well, which is in the controlled substance therapeutic space, and advancing our specialty pharmaceutical internal pipeline.

Within the pain treatment arena, we will continue to strive for a balance between access to pain management medications for legitimate patients with appropriate use and disposal to help combat abuse and diversion. That’s where our focus has been and will continue to be.

Where can readers find more information?

http://www.mallinckrodt.com/

https://nabp.pharmacy/

About Mark Trudeau and Carmen Catizone

Mark C. Trudeau is President and Chief Executive Officer of Mallinckrodt Pharmaceuticals.

Carmen Catizone is the Executive Director, National Association of Boards of Pharmacy (NABP),Secretary of the NABP Executive Committee, and also serves as a member of the Board of Governors on the Pharmacy Technician Certification Board and as Chair of the Certification Council.

April Cashin-Garbutt

Written by

April Cashin-Garbutt

April graduated with a first-class honours degree in Natural Sciences from Pembroke College, University of Cambridge. During her time as Editor-in-Chief, News-Medical (2012-2017), she kickstarted the content production process and helped to grow the website readership to over 60 million visitors per year. Through interviewing global thought leaders in medicine and life sciences, including Nobel laureates, April developed a passion for neuroscience and now works at the Sainsbury Wellcome Centre for Neural Circuits and Behaviour, located within UCL.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cashin-Garbutt, April. (2022, September 07). Combating prescription drug abuse: an interview with Mark Trudeau and Carmen Catizone. News-Medical. Retrieved on May 16, 2024 from https://www.news-medical.net/news/20140916/Combating-prescription-drug-abuse-an-interview-with-Mark-Trudeau-and-Carmen-Catizone.aspx.

  • MLA

    Cashin-Garbutt, April. "Combating prescription drug abuse: an interview with Mark Trudeau and Carmen Catizone". News-Medical. 16 May 2024. <https://www.news-medical.net/news/20140916/Combating-prescription-drug-abuse-an-interview-with-Mark-Trudeau-and-Carmen-Catizone.aspx>.

  • Chicago

    Cashin-Garbutt, April. "Combating prescription drug abuse: an interview with Mark Trudeau and Carmen Catizone". News-Medical. https://www.news-medical.net/news/20140916/Combating-prescription-drug-abuse-an-interview-with-Mark-Trudeau-and-Carmen-Catizone.aspx. (accessed May 16, 2024).

  • Harvard

    Cashin-Garbutt, April. 2022. Combating prescription drug abuse: an interview with Mark Trudeau and Carmen Catizone. News-Medical, viewed 16 May 2024, https://www.news-medical.net/news/20140916/Combating-prescription-drug-abuse-an-interview-with-Mark-Trudeau-and-Carmen-Catizone.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Biden is right. The US generally pays double that of other countries for Rx drugs.